130 results about "Lysophosphatidylcholine" patented technology

The present invention provides methods and compositions useful for the diagnosis or prognosis of a systemic inflammatory condition such as sepsis.

Mixtures of natural phosphatidylcholine species, natural lysophosphatidylcholine species, phosphatidylserine species, phosphatidylethanolamine species, 1-hydroxy-2-acyl-phosphatidylcholine species, 1-hydroxy-2-acyl-phosphatidylserine molecular species, 1-hydroxy-2-acyl-phosphatidylethanolamine molecular species, 1-O-alkyl-2-hydroxy phosphatidylcholine species, 1-O-alkyl-2-docosaheaxnoyl phosphatidylcholine species 1-O-alkyl-2-docosahexaenoyl phosphatidylserine species, and 1-O-alkyl-2-docosahexaenoyl phosphatidylethanolamine species, Methods using the above disclosed mixtures in mammals to treat various conditions.

The present invention provides methods and compositions useful for the diagnosis or prognosis of a systemic inflammatory condition such as sepsis.

The present invention relates to methods, monitors and systems measuring lysophosphatidylcholine, its derivatives and / or procalcitonin as well as at least one clinical marker (e.g. temperature or respiration rate) and / or at least one biomarker for the early detection of sepsis in a subject.

The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.

The present invention belongs to the technical field of screening and identification of nephrotic syndrome markers, and provides nephrotic syndrome progression-related metabolic markers and application thereof. Bis(4-ethylbenzyl)sorbitol, C16 d-sphinganine, lysophosphatidylethanolamine (LPE) (22:6), lysophosphatidylcholine (LPC) (22:5), N-ethanolamine and proline are taken as progressive markers; oleic acid amide, docosahexaenoic acid, 14S-hydroxy-docosahexaenoic acid, docosapentaenoic acid, uric acid, and LPC (20:5) and (18:1) are taken as early markers; and acylcarnitine (C18:0), linoleic acid carnitine, LPC (18:3), DL-tryptophan, indoleacrylic acid, p-cresol sulfate, 3-indol sulfate, cytosine, creatinine, sphingosine-1-phosphoric acid, L-aleuritic-dihydrosphingosine and ceramide (d18:0 / 14:0) are taken as late markers. The nephrotic syndrome progression-related metabolic markers provided by the present invention can be quantified, are fast, and have high sensitivity and strong specificity.

The invention discloses a method for preparing high-purity lysophosphatidylcholine. The method comprises the steps of enabling soybean phospholipid to dissolve in water or a calcium chloride solution,adding phospholipase, and performing an enzymolysis reaction; pretreating enzymolysis reaction products, conveying the pretreated enzymolysis reaction products into a silica gel column, performing repeated eluting by using multi-halogeno low-carbon alkane-low-carbon alcohol-water as an eluant, collecting a solution of an object, and performing concentration and drying so as to obtain high-puritylysophosphatidylcholine products. According to the method disclosed by the invention, ordinary soybean phospholipid is used as a raw material, through the enzymolysis reaction, pretreatment after enzymolysis and column chromatography and refiningtechnology, and the high-purity lysophosphatidylcholine is prepared; and the high-purity lysophosphatidylcholine has the characteristics that the raw materials are cheap and easy to obtain, the technology is simple, the maneuverability is high and product yield is high, is suitable for industrialized production, and the produced lysophosphatidylcholineis high in purity, few in by-products and stable in product quality.

The present invention relates to a pharmaceutical composition for preventing and / or treating metabolic bone disease. The pharmaceutical composition comprises an effective dose of an N-acyl lysophosphatidylcholine compound (chemical formula 1) and a carrier thereof that can be used in pharmaceutical preparations . Furthermore, the present invention relates to a preparation method for preparing the N-acyl lysophosphatidylcholine compound of Chemical Formula 1 from serine.

The invention discloses a quantitative analysis method for phosphatidylcholine in serum through capillary electrophoresis-mass spectrum and application. The quantitative analysis method includes the steps of S1, serum sample treating, wherein a serum sample is taken and added into a phosphatidylcholine internal standard substance, methyl alcohol is directly added, incubation on ice is carried out,centrifugation is carried out, supernatant is transferred, the product is dried with nitrogen and stored, and is dissolved with the methyl alcohol before CE-MS quantitative analysis, supernatant is removed through centrifugation, and capillary electrophoresis sample feeding is prepared, wherein the phosphatidylcholine internal standard substance is phosphatidylcholine 17:0 / 14:1, MW 717.996; S2, capillary electrophoresis condition conducting; S3, mass spectrum condition conducting; S4, quantitative analysis, wherein according to the concentration and the peak area of a standard solution, linear regression is carried out, a linear equation is obtained, and then according to the liner equation and the peak area obtained through detection, the concentration of the phosphatidylcholine and theconcentration of lysophosphatidylcholine in the serum sample are calculated. The application of the method is the application to detecting alzheimer disease. Relative quantitative analysis is carriedout on the PC / PLC in the serum in a multistage reaction monitoring mode (MRM), a large quantity of interfering ions are excluded, the detection limit is 0.0001 ng / mu L, the reproducibility is good, and the recycling rate and the detection sensitivity are high.